ArticleFrontiers in cellular and infection microbiology2026
Carbapenem-resistant enterobacterales in sterile body fluids: ten-year population genomics and clinical risk factors in a tertiary hospital, 2016-2025.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To clarify the molecular epidemiology, resistance gene profiles, virulence characteristics, and clinical prognosis-related factors of Carbapenem-Resistant Enterobacterales (CRE) isolated from sterile body fluids. This study provides microbiological evidence for clinical management and infection control surveillance. Methods: 62 non-duplicate sterile fluid CRE strains from 2016-2025 were retrospectively analyzed. VITEK-2 Compact detected MICs per CLSI M100. Illumina NovaSeq whole-genome sequencing was assembled via ABySS and GapCloser. Databases analyzed resistance, virulence, plasmid and MLST profiles. SNP phylogenetic analysis identified clonal clusters and strain genetic relationships. Results: Among the 62 CRE isolates, Klebsiella pneumoniae was the predominant species (77.4%, 48/62), followed by Escherichia coli (12.9%, 8/62) and Enterobacter cloacae complex (6.5%, 4/62). Additionally, single isolates of Klebsiella aerogenes and Citrobacter freundii were recovered. A total of 6 sequence types (STs) were identified, with ST11 being the most prevalent (87.5%, 42/48) among K. pneumoniae isolates. Carbapenemase genes were detected in 91.7% (44/48) of K. pneumoniae strains, with blaKPC-2 (85.4%, 41/48) and blaNDM-1 (10.4%, 5/48) as the main types. Three strains co-harbored blaKPC-2 and blaNDM-1, and one strain carried blaNDM-5 alone. These strains also carried class C β-lactamase (AmpC), extended-spectrum β-lactamases (ESBLs), and aminoglycoside/quinolone resistance genes. The rmpA2 virulence gene was detected in 75.0% (36/48) of K. pneumoniae isolates. Among E. coli, blaNDM-5 (4/8) and blaNDM-13 (2/8) were predominant. One ST155 isolate exhibited ertapenem resistance potentially mediated by AmpC promoter mutations and porin loss based on genomic prediction. Additionally, mcr-1.1 was detected in one ST361 isolate. All four E. cloacae complex belonged to ST171 and harboured blaNDM-1; one co-carried mcr-9.1. Clonal analysis revealed five major clusters within ST11 (Clade A-E), with Clade B comprising genetically related dual-carbapenemase isolates from multiple wards (8-10 SNPs). Twelve patients (19.4%) died. Intensive Care Unit (ICU) admission was significantly associated with mortality (83.3% vs. 30.0%, P=0.002). Conclusions: CRE from sterile body fluids were dominated by ST11 K. pneumoniae carrying blaKPC-2, with complex multidrug resistance and frequent carriage of rmpA2 and other virulence-associated genes. Continuous molecular surveillance of dominant clones and monitoring of high-risk patient populations may inform strategies to reduce CRE burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.